Legacy Healthcare Announces EMA Validation of Marketing Authorisation Application (MAA) for Coacillium for the treatment of Moderate and Severe Alopecia Areata in Children and Adolescents

LAUSANNE, Switzerland, June 19, 2023 /PRNewswire/ — Legacy Healthcare (or the “Company”), today announced that its Marketing Authorisation Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for Coacillium for the treatment of moderate and severe alopecia areata in children and adolescents has been validated and is now … Read more